Alnylam Pharmaceuticals misses Q2 street views (ALNY:NASDAQ)
· seekingalpha.com
Alnylam (ALNY) Q2 results: EPS and revenue miss, but 2026 guidance shifts—lower TTR product sales, higher royalties/collabs.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...